ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P ASX 200
7,968.20
0.60%
S&P ASX All Technology
3,399.00
0.55%
Brent Oil
65.78
0.02%
US Dollar vs AUD
1.56455
0.14%
Bitcoin
95,156.83
1.26%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Windtree Therapeutics Inc (WINT) Share Price

Windtree Therapeutics Inc

Windtree Therapeutics Inc (WINT)

NASDAQ
1.1806
0.0106
( 0.91% )
Updated: 01:23:56
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.1806
Bid
1.18
Offer
1.19
Volume
21,926
1.15 Day's Range 1.19
1.01 52 Week Range 737.435
Market Cap
4.198M
Previous Close
1.17
Open
1.16
Last Trade
4
@
1.185
Last Trade Time
01:27:02
Financial Volume
US$ 25,654
VWAP
1.17
Average Volume (3m)
7,347,464
Shares Outstanding
3,555,953
Dividend Yield
-
PE Ratio
-0.75
Earnings Per Share (EPS)
-1.54
Revenue
-
Net Profit
-5.49M

About Windtree Therapeutics Inc

Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants with... Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.windtreetx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Windtree Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker WINT. The last closing price for Windtree Therapeutics was US$1.17. Over the last year, Windtree Therapeutics shares have traded in a share price range of US$ 1.01 to US$ 737.435.

Windtree Therapeutics currently has 3,555,953 shares in issue. The market capitalisation of Windtree Therapeutics is US$4.16 million. Windtree Therapeutics has a price to earnings ratio (PE ratio) of -0.75.

Ask ADVFN Intelligence (AI)

WINT Latest News

More News

Form 8-K/A - Current report: [Amend]
Edgar (US Regulatory)
26 March 2025
WINT (0.91%)

Form 8-K - Current report
Edgar (US Regulatory)
25 March 2025
WINT (0.91%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.07066.360360360361.111.191.011286521.11966876CS
4-0.5194-30.55294117651.71.71.013583081.28546937CS
12-5.5694-82.50962962966.7510.7851.0173474645.45975962CS
26-41.0894-97.207002602342.2745.51.0150106618.00016073CS
52-260.8194-99.549389313262737.4351.01308500448.03579131CS
156-35998.8194-99.996720555636000396001.0116592234852.53279784CS
260-312748.8194-99.999622513127504527001.01126426525449.7053324CS

WINT - Frequently Asked Questions (FAQ)

What is the current Windtree Therapeutics share price?
The current share price of Windtree Therapeutics is US$ 1.1806
How many Windtree Therapeutics shares are in issue?
Windtree Therapeutics has 3,555,953 shares in issue
What is the market cap of Windtree Therapeutics?
The market capitalisation of Windtree Therapeutics is USD 4.16M
What is the 1 year trading range for Windtree Therapeutics share price?
Windtree Therapeutics has traded in the range of US$ 1.01 to US$ 737.435 during the past year
What is the PE ratio of Windtree Therapeutics?
The price to earnings ratio of Windtree Therapeutics is -0.75
What is the reporting currency for Windtree Therapeutics?
Windtree Therapeutics reports financial results in USD
What is the latest annual profit for Windtree Therapeutics?
The latest annual profit of Windtree Therapeutics is USD -5.49M
What is the registered address of Windtree Therapeutics?
The registered address for Windtree Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Windtree Therapeutics website address?
The website address for Windtree Therapeutics is www.windtreetx.com
Which industry sector does Windtree Therapeutics operate in?
Windtree Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RTCBaijiayun Group Ltd
US$ 0.3615
(94.88%)
151.21M
OMEXOdyssey Marine Exploration Inc
US$ 1.365
(60.19%)
217.07M
AGMHAGM Group Holdings Inc
US$ 0.0616
(57.95%)
299.35M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.275
(43.99%)
27.4M
GREEGreenidge Generation Holdings Inc
US$ 1.1289
(31.67%)
2.28M
CGTLCreative Global Technology Holdings Ltd
US$ 2.43
(-60.16%)
1.04M
COEPCoeptis Therapeutics Holdings Inc
US$ 7.5498
(-39.46%)
475.7k
INTSIntesity Therapeutics Inc
US$ 0.58
(-35.56%)
1.57M
SAIASaia Inc
US$ 262.44
(-25.91%)
1.68M
INVZWInnoviz Technologies Ltd
US$ 0.0613
(-25.70%)
11k
AGMHAGM Group Holdings Inc
US$ 0.0616
(57.95%)
299.35M
GNLNGreenlane Holdings Inc
US$ 0.01205
(-19.67%)
245.95M
OMEXOdyssey Marine Exploration Inc
US$ 1.365
(60.19%)
217.07M
RTCBaijiayun Group Ltd
US$ 0.3615
(94.88%)
151.21M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.0813
(15.35%)
135.67M

WINT Discussion

View Posts
Monksdream Monksdream 2 weeks ago
WINT, 10Q due Thursday 4/17
👍️0
nowwhat2 nowwhat2 1 month ago
Did somebody mention rveginas ?
👍️0
makinezmoney makinezmoney 1 month ago
$WINT: Who doesn't love Vaginal News

Am I right Ladies ???


GO $WINT
👍️0
glenn1919 glenn1919 1 month ago
WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 1 month ago
Vaginal news followed up by compliance news this morning  $3.55 + 40% . Be wise low float 800k but offering comes eventually 
👍️0
glenn1919 glenn1919 1 month ago
WINT.......................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
gapole gapole 1 month ago
Power hour...wint at 2.16...will it get pumped at eod??
👍️0
makinezmoney makinezmoney 1 month ago
$WINT: We're going to $5 before EOD

You heard it here first....................... Don't be scared now


GO $WINT
👍️0
makinezmoney makinezmoney 1 month ago
$WINT; $3.40 babyyyyyyyyyyyyyyyyyyyyyyyyy

Whos havin a good time............ talk to me now


GO $WINT
👍️0
makinezmoney makinezmoney 1 month ago
$WINT: Bring on the $3 breaker baby


You know you wannnnaaaaaaaaaaaaaaaaaaaaaaaa

Do it for DADDY


GO $WINT
👍️0
makinezmoney makinezmoney 1 month ago
$WINT: Now 2.70 ....................

Holla back if you making money off my CALLOUTS !!!!!!!!!!!!!!!

Love to hear from you.

Keep on ROcking in the Free World............ while its still a Free World




GO $WINT
👍️0
glenn1919 glenn1919 1 month ago
WINT.........................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
makinezmoney makinezmoney 1 month ago
$WINT: Going on News...............




GO $WINT
👍️0
makinezmoney makinezmoney 1 month ago
$WINT: The bottom is in............ look at 200day chart

Shes gonna get to $3 today

GO $WINT
👍️0
makinezmoney makinezmoney 1 month ago
$WINT: BOoommmmmmmmmmmm.... now $2.20

Thar she blowwwwwwwwwssssssssssssss


GO $WINT
👍️0
glenn1919 glenn1919 2 months ago
WINT........................................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
WINT EXPLOSION
👍️ 1
TrendTrade2016 TrendTrade2016 2 months ago
WINT POST SPLIT MOVE
👍️0
Monksdream Monksdream 2 months ago
WINT, new 52 week low
👍️ 1
getmoreshares getmoreshares 2 months ago
RS info -1 for 50- feb 20--Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.
The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) on February 21, 2025 at market open under the existing ticker symbol, “WINT.” The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.
👍️0
big bambino big bambino 2 months ago
big uptick on GNS also 😅
👍️0
big bambino big bambino 2 months ago
nice move 😁
👍️0
glenn1919 glenn1919 2 months ago
WINT.............................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 2 months ago
.2530 + 58%
👍️0
valleybenedetto valleybenedetto 2 months ago
Jumped in today .125 heavy
👍️0
getmoreshares getmoreshares 3 months ago
great site- thanks RS 5 to 50 Vote Approved
👍️0
bigbux1 bigbux1 3 months ago
Scroll 9 down...https://dilutiontracker.com/app/reverse-split
👍️0
getmoreshares getmoreshares 3 months ago
RS approved- no ratio announced yet
👍️0
BigJuan BigJuan 3 months ago
$WINT Hmm reversal here starting? Maybe run before 2/3 meeting.
👍️0
big bambino big bambino 3 months ago
checked for reason on surge and nothing visible, even on website
👍️0
Mr. Zen Mr. Zen 4 months ago
today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic shock due to heart failure. The presentation was given at the Cardiovascular Clinical Trials Conference in Washington, DC.

Dr. Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and an expert in heart failure and cardiogenic shock. He is part of the task force that wrote the 2021 ESC/HFA Guidelines of Heart Failure and the 2023 addendum.
👍️ 1 🚀 1
Monksdream Monksdream 5 months ago
WINT, new 52 low
👍️0
Monksdream Monksdream 5 months ago
WINT 10Q due 11/11
👍️0
Mr. Zen Mr. Zen 6 months ago
Took another position here, this could very easily be a $30.00 stock in 2 years, patience pays.
👍️ 1
tw0122 tw0122 6 months ago
Ping pong .80s to $1s
👍️0
Mr. Zen Mr. Zen 6 months ago
This may be the bottom for a longer term play,if they are successful with phase three it will be a $30.00 +/- stock. IMO
👍 2
glenn1919 glenn1919 6 months ago
WINT.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 6 months ago
WINT take smaller gain .94s to $1.20 exit having trouble on bigger breakout to $1.40s
👍️0
tw0122 tw0122 6 months ago
1.11 test again
👍️0
tw0122 tw0122 6 months ago
WINT $1.11 breakout solid and $1.44
Up next 3m floater
👍️0
Mr. Zen Mr. Zen 6 months ago
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.
👍️0
Monksdream Monksdream 6 months ago
WINT new 52 week low
👍️0
Monksdream Monksdream 7 months ago
WINT new 52=week low
👍️0
Roadtojourney Roadtojourney 7 months ago
Yup they pr only to dilute there share pos?? Imo
👍️0
Mr. Zen Mr. Zen 7 months ago
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.
👍️0
tw0122 tw0122 7 months ago
$1.26 + 36%
👍️0
tw0122 tw0122 7 months ago
Pump it
👍️0
Monksdream Monksdream 7 months ago
WINT anew 52 week low
👍️0
Monksdream Monksdream 7 months ago
WINT under $2
👍️0
Mr. Zen Mr. Zen 7 months ago
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
👍️ 1

Your Recent History

NASDAQ
WINT
Windtree Therapeutics
Delayed Upgrade Clock
ADVFN Logo
Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads